The EMPA-REG OUTCOME trial (Zinman et al., 2015) established cardioprotective effects of empagliflozin in high-risk diabetic patients, but the underlying mechanisms remain elusive. A recent hypothesis proposed that increased ketone oxidation contributed to the effect, but several caveats indicate that the role of myocardial ketone oxidation is far from clear.
